BioPharmaSpec scientists use peptide mapping to assess biopharmaceutical products for important Post Translational Modifications (PTMs) such as:

Peptide mapping is the generation of specific protease digests of the biopharmaceutical followed by analysis of these digest products using on-line Reverse Phase-High Performance Liquid Chromatography with Ultraviolet (UV) and Electrospray-Mass Spectrometric detection (LC/ES-MS).

Pretty Permethyl Glycan Spectra (L10_MS_6) copy

These experiments provide molecular weight information for the peptides released from the product using the protease of choice. The data obtained are able to provide mapping confirmation of the DNA-derived sequence, but not confirmation of the primary (de novo) sequence of the protein.